Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-vaccination pregnancy safety follow-up after RSVPreF3 maternal vaccination
2022-003124-41Phase 3Completed
- Sponsor
- GSK
- Start
- Jan 2023
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of GSK3003899A in respiratory syncytial virus disease (RSV) (2 arms), sponsored by GSK. Started Jan 2023; status: completed.
02
Drugs
GSK3003899A
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2022-003124-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003124-41.